Company intelligence / Profile preview

Korro Bio

Cambridge, Massachusetts, United States

Ownership: Public · KRRO
Employees: ~80
Development stage: Other

Overview

Korro Bio's lead program, KRRO-110 for Alpha-1 antitrypsin deficiency, entered Phase 1/2a clinical study in 2025 with interim data anticipated later in the year. Additional preclinical programs target CNS and liver diseases. The company recently executed a workforce reduction to extend cash runway and support clinical readouts.[1][2][3]

Therapeutic areas: NeurologyRare DiseasesMetabolic DisordersGastroenterology
Modalities: Antisense oligonucleotideRNA therapy
Industry: Biotech

Partnerships

Novo Nordisk (up to $530 million research collaboration and potentially other undisclosed partnerships)[3]

Beyond the preview

Go deeper on Korro Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Korro Bio.

Explore the full profile